BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma
November 19, 2021 06:30 ET | BioNTech SE
MAINZ, GERMANY, November 19, 2021 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for BNT111,...
BioNTech erhält FDA-Fast-Track-Status für FixVac-Kandidaten BNT111 bei fortgeschrittenem Melanom
November 19, 2021 06:30 ET | BioNTech SE
MAINZ, Deutschland, 19. November 2021 — BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass die US-amerikanische Arzneimittelbehörde (Food and Drug Administration,...
Sunshine Biopharma Logo
Sunshine Biopharma Expands Board of Directors
November 03, 2021 12:35 ET | Sunshine Biopharma Inc.
MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
BioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting
October 01, 2021 08:12 ET | BioNTech SE
MAINZ, Germany, October 1, 2021 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a next generation immunotherapy company pioneering novel therapies for cancer and...
BioNTech präsentiert neue klinische und präklinische Daten aus mehreren Immunonkologie-Programmen auf der 36. Jahrestagung der SITC
October 01, 2021 08:12 ET | BioNTech SE
MAINZ, Deutschland, 1. Oktober 2021 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“), ein Unternehmen, das zukunftsweisende Immuntherapien der nächsten Generation zur...
BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients
October 01, 2021 02:00 ET | BioNTech SE
Second Phase 2 trial initiated from BioNTech’s proprietary individualized mRNA-based cancer vaccine platform iNeST Randomized Phase 2 trial will enroll approximately 200 patients with high-risk...
BioNTech erweitert klinisches Onkologie-Portfolio: Erster Patient in Phase 2-Studie mit individualisierter mRNA-basierter Immuntherapie BNT122 gegen Darmkrebs behandelt
October 01, 2021 02:00 ET | BioNTech SE
Zweite Phase-2-Studie initiiert, die auf BioNTechs unternehmenseigener individualisierter mRNA-basierten Krebsimpfstoff-Plattform iNeST basiert Randomisierte Phase-2-Studie wird rund 200 Patienten mit...
Sunshine Biopharma Logo
Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement
July 27, 2021 09:00 ET | Sunshine Biopharma Inc.
MONTREAL, July 27, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
Sunshine Biopharma Logo
Sunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer
July 08, 2021 09:00 ET | Sunshine Biopharma Inc.
MONTREAL, July 08, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma
June 18, 2021 05:00 ET | BioNTech SE
First program from BioNTech’s fully-owned mRNA cancer vaccine platform FixVac treats patients in a randomized clinical Phase 2 clinical trial Phase 2 trial is based on positive results from Phase 1...